Search results

Dogra, T.; Pelz, L.; Rüdiger, D.; Hein, M.; Baelkner, M.; Boehme, J.D.; Marichal-Gallardo, P.; Genzel, Y.; Bruder, D.; Kupke, S. Y. et al.; Reichl, U.: Genetically engineered defective interfering particles of influenza A virus for antiviral treatment and vaccination. 9^th European Congress of Virology (ECV), Cavtat/Dubrovnik (Croatia) (2025)

Jacobtorweihe, L.; Braatz, F.; Brice, M.; Léon, A.; Genzel, Y.; Reichl, U.: Intensification of oncolytic Newcastle disease virus production using EB66 duck cells in perfusion mode. 5^th ESACT Frontiers Retreat, Ljubljana (Slovenia) (2025)

Jacobtorweihe, L.; Braatz, F.; Madeline, B.; Léon, A.; Genzel, Y.; Reichl, U.: Production of Oncolytic Newcastle Disease Virus in EB66 cells: Characterization of Parameters for Process Intensification. Cell Culture Engineering (CCE) XIX, Tucson Arizona (USA) (2025)

Küchler, J.; Opitz, P.; Jordan, I.; Genzel, Y.; Benndorf, D.; Reichl, U.: Quantification of intracellular influenza A virus proteins shows changes in dynamics related to host cell line and virus seed. 9^th European Congress of Virology (ECV), Cavtat/Dubrovnik (Croatia) (2025)

Dogra, T.; Pelz, L.; Rüdiger, D.; Hein, M. D.; Böhme, J.; Bälkner, M.; Kershaw, O.; Marichal-Gallardo, P.; Gruber, A.; Genzel, Y. et al.; Bruder, D.; Kupke, S. Y.; Reichl, U.: Genetically engineered defective interfering particles for antiviral treatment and vaccination. 28th ESACT Meeting, Edingburgh (Scotland) (2024)

Jacobtorweihe, L.; Göbel, S.; Wolschek, M.; Altomonte, J.; Reichl, U.; Genzel, Y.: HCD Perfusion of CCX.E10 Quail Cells for Production of Vesicular Stomatitis Virus based oncolytic Vaccine. Vaccine Technology IX, Los Cabos (Mexico) (2024)

Jacobtorweihe, L.; Göbel, S.; Wolschek, M.; Altomonte, J.; Reichl, U.; Genzel, Y.: Production of Oncolytic rVSV-NDV in CCX.E10 Quail Cells by HCD Perfusion Culture. Himmelfahrtstagung on Bioprocess Engineering 2024, Regensburg (Germany) (2024)

Jacobtorweihe, L.; Madeline, B.; Léon, A.; Genzel, Y.; Reichl, U.: Production of Oncolytic Newcastle Disease Virus in EB66 cells. 28th ESACT Meeting, Edingburgh (Scotland) (2024)

Küchler, J.; Opitz, P.; Jordan, I.; Genzel, Y.; Benndorf, D.; Reichl, U.: Quantification of intracellular influenza A virus proteins shows changes in dynamics related to host cell line and virus seed. 28th ESACT Meeting , Edingburgh (Scotland) (2024)

Küchler, J.; Opitz, P.; Jordan, I.; Genzel, Y.; Benndorf, D.; Reichl, U.: Quantification of intracellular influenza A virus proteins shows changes in dynamics related to host cell line and virus seed. Himmelfahrtstagung on Bioprocess Engineering 2024, Regensburg (Germany) (2024)

Zinnecker, T. M.; Thiele, K.; Schmidberger, T.; Reichl, U.; Genzel, Y.: Influenza A Virus Production following Quality by Design Principles. Vaccine Technology IX, Los Cabos (Mexico) (2024)

Zinnecker, T. M.; Thiele, K.; Schmidberger, T.; Reichl, U.; Genzel, Y.: Implementation of Quality by Design Principles for Influenza A Virus Production. 28th ESACT Meeting, Edingburgh (Scotland) (2024)

Dogra, T.; Pelz, L.; Rüdiger, D.; Hein, M. D.; Baelkner, M.; Julia D. Boehme, J. D.; Marichal-Gallardo, P.; Genzel, Y.; Bruder, D.; Kupke, S. Y. et al.; Reichl, U.: Genetically engineered defective interfering particles of influenza A virus for antiviral treatment and vaccination. 32^nd Annual Meeting of the Society for Virology (GfV), Ulm (Germany) (2023)

Dogra, T.; Pelz, L.; Rüdiger, D.; Hein, M. D.; Baelkner, M.; Julia D. Boehme, J. D.; Marichal-Gallardo, P.; Genzel, Y.; Bruder, D.; Kupke, S. Y. et al.; Reichl, U.: Genetically engineered defective interfering particles of influenza A virus for antiviral treatment and vaccination. 8^th European Congress of Virology, Gdańsk (Poland) (2023)

Küchler, J.; Opitz, P.; Kupke, S. Y.; Genzel, Y.; Benndorf, D.; Reichl, U.: Absolute quantification of viral proteins during single-round replication of vaccine producer cell lines. 32^nd Annual Meeting of the Society for Virology (GfV) , Ulm (Germany) (2023)

Küchler, J.; Opitz, P.; Kupke, S. Y.; Genzel, Y.; Benndorf, D.; Reichl, U.: Absolute quantification of influenza A virus proteins during single-round replication in vaccine producer cell lines. 16^th PEACe (Protein Expression in Animal Cells) Conference, Sitges (Spain) (2023)

Pelz, L.; Dogra, T.; Boehme, J.D.; Hein, M. D.; Marichal-Gallardo, P.; Genzel, Y.; Bruder, D.; Kupke, S. Y.; Reichl, U.: Influenza A virus OP7 defective interfering particles: Cell culture-based production and antiviral efficacy in vivo. Cell Culture Engineering (CCE) XVIII , Cancun (Mexico) (2023)

Pelz, L.; Dogra, T.; Boehme, J.D.; Marichal-Gallardo, P.; Hein, M. D.; Genzel, Y.; Bruder, D.; Kupke, S. Y.; Reichl, U.: A Scalable High-Yield Process for Production of Influenza A Virus Defective Interfering Particles and In Vivo Studies. Himmelfahrtstagung on Bioprocess Engineering 2023, Weimar (Germany) (2023)

Pelz, L.; Dogra, T.; Boehme, J.D.; Marichal-Gallardo, P.; Hein, M. D.; Genzel, Y.; Bruder, D.; Kupke, S. Y.; Reichl, U.: Influenza A Virus Chimeric OP7 Defective Interfering Particles: Cell Culture-based Production and In Vivo Antiviral Efficacy. 32^nd Annual Meeting of the Society for Virology (GFV), Ulm (Germany) (2023)

Göbel, S.; Dorn, M.; Jaén Chavez, K.; Jordan, I.; Sandig, V.; Altomonte, J.; Genzel, Y.; Reichl, U.: Production of a fusogenic oncolytic rVSV-NDV virus in perfusion processes. Vaccine Technology VIII, Sitges (Spain) (2022)